ZLc-002

ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation[1][2][3].

Product Specifications

CAS Number

[1446971-41-0]

UNSPSC

12352211

Target

NO Synthase

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/zlc-002.html

Solubility

10 mM in DMSO

Smiles

COC(CC(N[C@H](C(C)C)C(OC)=O)=O)=O

Molecular Formula

C10H17NO5

Molecular Weight

231.25

References & Citations

[1]Ni HY, et al.Dissociating nNOS (Neuronal NO Synthase) -CAPON (Carboxy-Terminal Postsynaptic Density-95/Discs Large/Zona Occludens-1 Ligand of nNOS) Interaction Promotes Functional Recovery After Stroke via Enhanced Structural Neuroplasticity. Stroke. 2019 Mar;50 (3) :728-737. |[2]Zhu LJ, et al. nNOS-CAPON blockers produce anxiolytic effects by promoting synaptogenesis in chronic stress-induced animal models of anxiety. Br J Pharmacol. 2020 Aug;177 (16) :3674-3690.|[3]Zhu LJ, et al.CAPON-nNOS coupling can serve as a target for developing new anxiolytics. Nat Med. 2014 Sep;20 (9) :1050-4. doi: 10.1038/nm.3644. Epub 2014 Aug 17.